Microsoft Eyes $7B Texas Energy Deal to Power AI Data Centers 
MATCH Act Targets ASML and Chinese Chipmakers in New U.S. Export Crackdown 
U.S. Automakers Push Back Against EU Rules Blocking American Trucks from European Market 
Apple's Foldable iPhone Faces Engineering Setbacks, Mass Production Timeline at Risk 
Nike Beats Q3 Estimates but China Weakness and Margin Pressure Weigh on Outlook 
TSMC Japan's Second Fab to Produce 3nm Chips by 2028 
Annie Altman Amends Sexual Abuse Lawsuit Against OpenAI CEO Sam Altman 
Britain Courts Anthropic Amid US Defense Department Dispute 
Elon Musk Ties SpaceX IPO Access to Mandatory Grok AI Subscriptions 
SpaceX IPO: Retail Investors to Play Historic Role in Record-Breaking Public Offering 
Samsung Electronics Eyes Record Q1 Profit Amid AI-Driven Chip Boom 
China Vanke Seeks Bond Extension Amid Mounting Debt Crisis 
Deere & Company Agrees to $99 Million Settlement Over Right-to-Repair Dispute 
Fonterra Admits Anchor Butter "Grass-Fed" Label Misled Consumers After Greenpeace Lawsuit 
Apple Turns 50: From Garage Startup to AI Crossroads 
Paramount Skydance Secures $24B from Gulf Sovereign Wealth Funds for Warner Bros. Discovery Takeover 
UAE's Largest Natural Gas Facility Suspended After Attack-Triggered Fire 
BRISBANE, Calif., June 26, 2017 -- KaloBios Pharmaceuticals, Inc. (OTCQB: KBIO), a biopharmaceutical company focused on advancing medicines for patients with neglected and rare diseases, today announced it has been approved for trading its stock on the OTCQB® Venture Market, upgrading from the Pink Market®.
The OTCQB is recognized as an Established Public Market by the U.S. Securities and Exchange Commission. The OTCQB trading standards require that companies be current in their regulatory filings, complete an annual verification and management certification, and have a minimum $0.01 bid price.
“Trading on the OTCQB is another incremental step forward in our strategy to improve the financial foundation of KaloBios, enhance liquidity in our stock and continue to build more trust in the investment community,” said Cameron Durrant, MD, chairman and CEO of KaloBios. “Meantime, we will continue to pursue the key corporate goal of uplisting to a national securities exchange.”
Investors and all stakeholders can find more information about the OTCQB market, quotes and other details at www.otcmarkets.com.
About KaloBios Pharmaceuticals, Inc.
KaloBios Pharmaceuticals, Inc. (OTCQB: KBIO) is an emerging biopharmaceutical company focused on advancing medicines for patients with neglected and rare diseases through innovative and responsible business models. Lead compounds in the KaloBios portfolio are benznidazole for the potential treatment of Chagas disease in the U.S., and the proprietary monoclonal antibodies, lenzilumab and ifabotuzumab. Lenzilumab has potential for treatment of various rare diseases, including hematologic cancers such as chronic myelomonocytic leukemia (CMML) and potentially juvenile myelomonocytic leukemia (JMML). For more information, visit www.kalobios.com.
CONTACT: Investors: Mike Cole O: 949-259-4988 C: 949-444-1341 [email protected] Media: Lisa Guiterman O: 301-217-9353 C: 202-330-3431 [email protected]
